/ lymphocyte proportion at month 1 of ú5% (HR, 32; 95% CI, 8.1 -126.4) were independently associated with the risk of herpes zoster. These data might be clinically useful for determining transient prophylaxis for those patients at high risk.
The introduction of protease inhibitors (PIs) has dramatically the efficacy and tolerability of the addition of a PI to baseline treatment with at least one NRTI (azidothymidine, dideoxyimproved the quality of life and survival rate for patients with inosine, or dideoxycitidine) [9] . Criteria for inclusion in that AIDS [1, 2] . However, the initial immunologic improvement study were diagnosis of AIDS [10] , treatment with an NRTI soon after the onset of treatment with protease inhibitors may for at least 6 months, no previous treatment with a PI, and contribute to a transient increase in the risk of some opportunisimmunologic failure, defined by a return of the CD4 / lymphotic infections such as cytomegalovirus retinitis [3] or mycobaccyte count to the baseline value. Enrollment started in June terial disease [4] . Although herpes zoster develops at a rela-1996 but was prematurely concluded in November 1996 when tively constant rate in HIV-1-infected patients, irrespective of stavudine (d4T), lamivudine (3TC), saquinavir, ritonavir, and the stage of the disease and type of antiretroviral therapy with indinavir became commercially available in Spain and the simnucleoside analogue reverse-transcriptase inhibitors (NRTIs) ple addition of a PI to baseline treatment was no longer the [5 -8], we have detected an increase in the incidence of herpes best option for changing a failing NRTI regimen. Measurement zoster occurring in persons with AIDS soon after the introducof CD4 / and CD8 / cells and of the plasma viral load (Amplicor tion of PIs.
HIV Monitor; Roche Diagnostics Systems, Nutley, NJ) was performed at baseline, 1 and 3 months, and every 3 months See editorial response by Daar on pages 1514 -6. thereafter. Herpes zoster was diagnosed clinically [11] . The estimated probability of surviving and remaining free of herpes zoster was assessed with a Kaplan-Meier analysis.
Patients and Methods
Risk factors for herpes zoster were analyzed univariately by the x 2 test and the Student's t test and multivariately by survival We prospectively collected all diagnosed cases of herpes regression models (Cox proportional hazards method). Besides zoster involving 193 patients in an open, randomized study of baseline characteristics, CD4 / and CD8 / cell counts and the plasma viral load at month 1 were considered as covariates in the analysis of risk factors for herpes zoster in the multivariate shown in figure 3 . By introduction of the most discriminative 
Discussion
Reactivation of the varicella-zoster virus as an episode of (7%) had a first episode or recurrence of herpes zoster after a herpes zoster is a well-recognized cause of morbidity in HIVmedian follow-up of 64 weeks (range, 34 -103 weeks). Zoster 1-infected patients [12] . All data concerning herpes zoster in was the most common opportunistic infection in that period, HIV-1-infected patients was generated before the introduction followed by cytomegalovirus disease (eight episodes) and tuof PIs. The reported incidence of herpes zoster among HIVberculosis (six episodes). The estimated probability of surviving and remaining free of herpes zoster is shown in figure 1 . No episodes of herpes zoster were diagnosed before week 4. Twelve (86%) of the 14 episodes were clustered between weeks 4 and 16. The incidence of herpes zoster for the whole period of follow-up was 6.2 episodes per 100 patient-years, but it increased to 26.9 episodes per 100 patient-years when only the interval between weeks 4 and 16 was considered.
All but one episode had a dermatomal distribution, and systemic symptoms were always absent. Acyclovir or famciclovir was administered orally in 11 episodes. Clinical evolution was uniformly good. The incidence of new or recurrent category C events [10] among patients with herpes zoster (3 of 14; 20.7%) was similar to that among patients without herpes zoster (37 of 179; 21.4%) (Student's t test, P ú .05). None of the 10 patients (5%) who died during the study had an episode of 1-infected individuals is Ç3 cases per 100 person-years, as more common in HIV-1-infected patients with low CD4 / lymphocyte counts (£200/mL) [14] . compared with a rate of Ç0.2 cases per 100 person-years among non-HIV-1-infected control populations [13] . The oc-
The incidence of herpes zoster in our cohort was twice higher than that previously described before the introduction of antiretcurrence of an episode of herpes zoster is not a reliable predictor of progression of HIV-1 infection. It can occur at a roviral therapy with PIs. Moreover, zoster episodes developed mainly between weeks 4 and 16 when the incidence of zoster relatively constant rate at any stage of HIV-1 infection, irrespective of the CD4 / lymphocyte count [5 -8]. However, comincreased ninefold. In spite of this high incidence, manifestations of herpes zoster were mild and no evolutive complications were plications of herpes zoster, such as ocular and neurological problems and persistence of chronic atypical skin lesions, are detected, in contrast to what has been previously reported [14] . Comparisons between quartiles 1 and 4 (P Å .08), 2 and 4 (P Å .07), and 3 and 4 (P Å .2) showed a trend toward statistical significance (log-rank test). In B, quartile 1 includes values between 023.4 and 02.7; quartile 2 includes values between 02.6 and 1.1; quartile 3 includes values between 1.2 and 5.4; and quartile 4 includes values between 5.4 and 41.7. Comparisons between quartiles 1 and 4 (P Å .0004), 2 and 4 (P Å .002), and 3 and 4 (P Å .006) were statistically significant (log-rank test).
